Cargando…

Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis

Fevipiprant is a non-steroidal oral prostaglandin D2 (PGD2) receptor 2 antagonist that reduces bronchial wall inflammation, possibly improving clinical outcomes in the asthmatic population. A systemic review search was conducted on PubMed, Embase, and Central Cochrane Registry. Randomized clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahangir, Abdullah, Sattar, Saud Bin Abdul, Rafay Khan Niazi, Muhammad, Muhammad, Marwah, Jahangir, Ahmad, Sahra, Syeda, Sharif, Muhammad Ans, Anwar, Muhammad Yasir, Chalhoub, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153206/
https://www.ncbi.nlm.nih.gov/pubmed/35663651
http://dx.doi.org/10.7759/cureus.24641
_version_ 1784717802327769088
author Jahangir, Abdullah
Sattar, Saud Bin Abdul
Rafay Khan Niazi, Muhammad
Muhammad, Marwah
Jahangir, Ahmad
Sahra, Syeda
Sharif, Muhammad Ans
Anwar, Muhammad Yasir
Chalhoub, Michel
author_facet Jahangir, Abdullah
Sattar, Saud Bin Abdul
Rafay Khan Niazi, Muhammad
Muhammad, Marwah
Jahangir, Ahmad
Sahra, Syeda
Sharif, Muhammad Ans
Anwar, Muhammad Yasir
Chalhoub, Michel
author_sort Jahangir, Abdullah
collection PubMed
description Fevipiprant is a non-steroidal oral prostaglandin D2 (PGD2) receptor 2 antagonist that reduces bronchial wall inflammation, possibly improving clinical outcomes in the asthmatic population. A systemic review search was conducted on PubMed, Embase, and Central Cochrane Registry. Randomized clinical trials were included with Fevipiprant as an intervention arm compared to placebo. For continuous variables, the standardized mean difference, and for discrete variables, Mantel-Haenszel Risk Ratio (MH Risk ratio) was used for analysis. Confidence interval of 95% and p-value < 0.05 was considered significant. The analysis was done using a random-effects model irrespective of heterogeneity. Heterogeneity was evaluated using the I2 statistic. A total of five articles, including seven trials, were included in the analysis. There was significant increase in post-bronchodilator forced expiratory volume in one second (FEV1) 0.249 (0.157-0.341), p<0.001 and pre-bronchodilator FEV1 0.115 (0.043 to 0.188), p=0.002. A decrease in asthma control questionnaire (ACQ) score of -0.124 (-0.187 to -0.062), p<0.001, was reported. Statistically significant asthma exacerbation reduction was reported in the high eosinophil count population with a daily dose of 450mg 0.77 relative risks (RR) (0.61-0.97). There was a positive deviation toward Fevipiprant 450mg dose for asthma reduction in the overall population, but it was not statistically significant. Fevipiprant produced a slight statistically significant reduction in asthma exacerbations in the high eosinophil count population with favorable deviation in the overall population. It significantly increased pre-and post-bronchodilator FEV1 and improved ACQ scores in treated patients. The benefits, though statistically significant, failed to translate into clinical importance.
format Online
Article
Text
id pubmed-9153206
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-91532062022-06-02 Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis Jahangir, Abdullah Sattar, Saud Bin Abdul Rafay Khan Niazi, Muhammad Muhammad, Marwah Jahangir, Ahmad Sahra, Syeda Sharif, Muhammad Ans Anwar, Muhammad Yasir Chalhoub, Michel Cureus Pulmonology Fevipiprant is a non-steroidal oral prostaglandin D2 (PGD2) receptor 2 antagonist that reduces bronchial wall inflammation, possibly improving clinical outcomes in the asthmatic population. A systemic review search was conducted on PubMed, Embase, and Central Cochrane Registry. Randomized clinical trials were included with Fevipiprant as an intervention arm compared to placebo. For continuous variables, the standardized mean difference, and for discrete variables, Mantel-Haenszel Risk Ratio (MH Risk ratio) was used for analysis. Confidence interval of 95% and p-value < 0.05 was considered significant. The analysis was done using a random-effects model irrespective of heterogeneity. Heterogeneity was evaluated using the I2 statistic. A total of five articles, including seven trials, were included in the analysis. There was significant increase in post-bronchodilator forced expiratory volume in one second (FEV1) 0.249 (0.157-0.341), p<0.001 and pre-bronchodilator FEV1 0.115 (0.043 to 0.188), p=0.002. A decrease in asthma control questionnaire (ACQ) score of -0.124 (-0.187 to -0.062), p<0.001, was reported. Statistically significant asthma exacerbation reduction was reported in the high eosinophil count population with a daily dose of 450mg 0.77 relative risks (RR) (0.61-0.97). There was a positive deviation toward Fevipiprant 450mg dose for asthma reduction in the overall population, but it was not statistically significant. Fevipiprant produced a slight statistically significant reduction in asthma exacerbations in the high eosinophil count population with favorable deviation in the overall population. It significantly increased pre-and post-bronchodilator FEV1 and improved ACQ scores in treated patients. The benefits, though statistically significant, failed to translate into clinical importance. Cureus 2022-05-01 /pmc/articles/PMC9153206/ /pubmed/35663651 http://dx.doi.org/10.7759/cureus.24641 Text en Copyright © 2022, Jahangir et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pulmonology
Jahangir, Abdullah
Sattar, Saud Bin Abdul
Rafay Khan Niazi, Muhammad
Muhammad, Marwah
Jahangir, Ahmad
Sahra, Syeda
Sharif, Muhammad Ans
Anwar, Muhammad Yasir
Chalhoub, Michel
Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
title Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
title_full Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
title_fullStr Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
title_full_unstemmed Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
title_short Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
title_sort efficacy and safety of fevipiprant in asthma: a review and meta-analysis
topic Pulmonology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153206/
https://www.ncbi.nlm.nih.gov/pubmed/35663651
http://dx.doi.org/10.7759/cureus.24641
work_keys_str_mv AT jahangirabdullah efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT sattarsaudbinabdul efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT rafaykhanniazimuhammad efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT muhammadmarwah efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT jahangirahmad efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT sahrasyeda efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT sharifmuhammadans efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT anwarmuhammadyasir efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis
AT chalhoubmichel efficacyandsafetyoffevipiprantinasthmaareviewandmetaanalysis